Image default
Women's Health

Heparan Sulfate Products for COVID-19 Infection, Disease & Therapeutics Research

AMSBIO offer a wide range of Heparan Sufate antibodies, enzymes, standards and ready-to-use Heparanase activity assays for researchers seeking to better understand COVID-19 and thereby to combat the pandemic.

Heparan Sulfate (HS) is increasingly recognised as a key factor in infection by the SARS-CoV-2 virus, which is the cause of the current COVID-19 Coronavirus pandemic. Using HS antibodies from AMSBIO, researchers have demonstrated that Heparanase enzyme contributes to the pathogenesis of COVID-19, with both Heparanase activity and HS levels being elevated in plasma of Covid-19 patients. In addition, recent published data has shown that Heparanase activity is further elevated in ICU patients on ventilators compared to less serious cases.

In particular, JM403 Heparan Sulfate antibody supplied by AMSBIO has been used in two novel assays developed and applied by Prof. Dr. Johan van der Vlag and colleagues at the Radboud University Medical Center, Nijmegen, Netherlands. They developed a JM403-based plasma heparanase activity assay, and a JM403-based HS competition ELISA to measure plasma HS levels**.

Prof. Dr. Johan van der Vlag said “The JM403 antibody from AMSBIO is a unique and powerful tool that is helping us develop new assays to measure plasma heparanase and HS levels in patients with COVID-19. A particular advantage of JM403 is that it is not reacting with heparins, which would have been a disturbing factor in our analyses, and which now allowed us to evaluate the effect of treating COVID-19 patients with low molecular weight heparins.”

For further information on Heparan Sulfate antibodies, enzymes, standards and kits to assist research into SARS-CoV-2 infection, disease and therapeutics please visit or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / [email protected].  

Source link

Related posts

Study outlines a new role for pregnancy-associated plasma protein A in gestational diabetes

Globe Health News

Poor sleep may be a risk factor for developing complicated grief after a loss

Globe Health News

Can metabolic biomarkers help clinicians stratify adverse outcome risk in COVID-19 patients?

Globe Health News

Leave a Comment